- Thinly traded nano cap Achieve Life Sciences (NASDAQ:ACHV) is up 54% premarket on increased volume in response to its announcement of positive results from a Phase 1/2 clinical trial evaluating cytisine in 24 healthy volunteer smokers over a 25-day treatment period.
- Pharmacokinetic data showed increases in plasma concentration between the standard and higher doses of cytisine with no evidence of drug accumulation. 58% (n=14/24) of smokers achieved abstinence on day 26, 50% (n=6/12) in the 1.5 mg arm and 67% (n=8/12) in the 3.0 mg arm. Those who were unable to quit entirely were smoking considerably less cigarettes per day at the end of treatment.
- On the safety front, most adverse events (AEs) were mild and transitory. The most frequent AE was transient headache.
- Cytisine is a plant-based alkaloid with a strong affinity to the nicotinic acetylcholine receptor.
- Phase 3 development will start mid-year.
- Now read: CNBC investigation into Riot Blockchain reveals investor with long history with tiny companies
Original article